Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: Administration for complex coronary intervention

Circulation

Volumn 94, Issue 5, 1996, Pages 906-910

  Kereiakes, Dean J ^a,c   Runyon, John Paul ^a   Kleiman, Neal S ^b   Higby, Nancy A ^c   Anderson, Linda C ^c   Hantsbarger, Gary ^d   McDonald, Shawn ^d   Anders, Robert J ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d PFIZER INC   (United States)

Author keywords

aggregation inhibitors; glycoproteins; platelets

Indexed keywords

ABCIXIMAB; XEMILOFIBAN;

ADULT; AGED; ARTICLE; ATHERECTOMY; BLEEDING TIME; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TARGET CELL; THROMBOCYTE AGGREGATION;

EID: 0029787575     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.5.906     Document Type: Article

References (9)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, duMee CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
3. Lincoff AM, Califf RM, Anderson K, Weisman HF, Topol EJ, for the EPIC Investigators. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: outcomes in the EPIC trial. Circulation. 1994;90(suppl I):I-21. Abstract.
4. Teirstein PS, Yakubov SJ, Thel MC, Wildermann N, Kereiakes DJ, Popma JJ, Lincoff MA, Tcheng JE, Califf RM, Topol EJ. Platelet IIb/IIIa blockade with integrelin: atherectomy patients. J Am Coll Cardiol 1996;27:334A. Abstract.
5. Lefkovits J, Anderson K, Weisman H, Topol EJ, for the EPIC Investigators. Increased risk of non-Q MI following DCA: evidence for a platelet dependent mechanism from the EPIC trial. Circulation. 1994;90(suppl I):I-214. Abstract.
6. Zidar JP, Kruse KR, Thel MC, Kereiakes DJ, Muhlestein JB, Davidson CJ, Teirstein PS, Tenaglia A, Yakubov SJ, Popma JJ, Tanguay JF, Kitt MM, Lorenz TJ, Tcheng JE, Lincoff AM, Califf RM, Topol EJ. Integrelin for emergency coronary artery stenting. J Am Coll Cardiol. 1996;27:138A. Abstract.
7. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
8. Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GPIIb/IIIa receptor blockade: a pilot study of xemilofiban, an orally active antagonist in unstable angina patients eligible for PTCA. J Am Coll Cardiol 1996;27:242A. Abstract.
9. Anders RJ, Alexander JC, Hantsbarger GL, Burns DM, Oliver SD, Cole G, Fitzgerald DJ. Demonstration of potent inhibition of platelet aggregation with an orally active GP IIb/IIIa receptor antagonist. J Am Coll Cardiol. February 1995;(special issue):117A. Abstract.